A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
Latest Information Update: 09 Jun 2025
At a glance
- Drugs Ivonescimab (Primary) ; Carboplatin; Paclitaxel; Pembrolizumab
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms HARMONi-3
- Sponsors Summit Therapeutics
Most Recent Events
- 24 Feb 2025 According to a Summit Therapeutics media release, enrollment has begun in United States for patients with non-squamous tumors.
- 20 Dec 2024 Planned End Date changed from 20 Dec 2027 to 31 Dec 2028.
- 20 Dec 2024 Planned primary completion date changed from 30 Sep 2027 to 31 Dec 2027.